40+ Presentations from Top Biopharma at PEGS Europe
The CD25 Antibody RG6292 Selectively Depletes Tregs while Preserving IL-2 Signaling and CTL Activity for Tumor ControlMaria Amann, Senior Scientist, Drug Development, Roche Innovation Center ZurichCombining Random Mutagenesis, Structure-Guided Design, Next-Generation Sequencing and in silico Prediction to Optimize Polyreactivity and Other Biophysical Properties in Therapeutic AntibodiesJames R. Apgar, PhD, Associate Research Fellow, Global Biotherapeutics Technologies, Pfizer Inc.Predicting Antibody Developability through Experimental and in silico ApproachesMarc Bailly, PhD, Principal Scientist, Merck Research LabsPD-1 Antibodies as Precision Medicine Informed Mono- and Combination Therapies Are Transforming Cancer CareRoy Baynes, MD, PhD, Senior Vice President & Head, Global Clinical Development; CMO, Merck, Sharp and DohmeLC-MS Characterization of Viral Vector-Based Gene Therapy ProductsJill Bradley-Graham, PhD, Scientist, BioAnalytics Characterization, Sanofi GenzymeDuoHexaBody-CD37Esther C.W. Breij, PhD, Senior Director, Translational Research, Translational Research, Genmab BVAccelerated Predictive Stability for Biologicals and VaccinesDidier Clenet, Senior Scientist, Formulation & Stability & Bioprocess R&D, Sanofi PasteurCharacterization of Half Antibodies and LC Swab Variants of a Bispecific Antibody during Clone SelectionManuel Diez, PhD, Functional Lead, Characterization, NovartisIs NMR Spectroscopy the Right Tool to Monitor the HOS of Biologics?Camille Doyen, PhD, Scientist, Biophysics, SanofiAntibody CDR Design Using High-Capacity Machine LearningStefan Ewert, PhD, Senior Investigator, Biologics Center, Novartis Institutes for Biomedical ResearchRational Selection of Building Blocks for the Assembly of Bispecific AntibodiesDanyang Gong, PhD, Scientist, Amgen Inc.How Analytical and Biological Characterization Translates into a Comprehensive and Smart Control Strategy for Commercial ManufacturingDirk Haubert, PhD, Analytical Project Lead, Biologics, Novartis Pharma AGA Novel Tumor Selective Anti-CD137 Agonist Antibody Activated by Elevated Extracellular ATP in Tumor MicroenvironmentYuji Hori, PhD, Research Scientist, Discovery Biological, Chugai Pharmaceutical Co. Ltd.Analytical Control Strategy for Antisense OligonucleotideHong Jiang, Senior Scientist, Analytical Development, BiogenDesign and Validation of a Novel Engineered, FcγRIIb-Selective Fc Platform for Therapeutic Antibody DevelopmentGavin C. Jones, PhD, Investigator, GlaxoSmithKlineDevelopment of a High-Throughput cIEF Method for Quantification of Full and Empty Viral Particles for Cell and Gene TherapiesJenifer Kaplan, PhD, Principal Scientist I, Novartis Institutes for Biomedical ResearchEngineering Antibodies for Next-Generation Cancer ImmunotherapyChristian Klein, PhD, Cancer Immunotherapy Discovery, Roche Innovation Center Zurich, Roche Pharma Research & Early Development, pREDIntrinsic Physiochemical Profile of Biological MedicinesSandeep Kumar, PhD, Senior Research Fellow, Computational Biochemistry and Bioinformatics, Boehringer Ingelheim PharmaceuticalsCharacterization and Mitigation of Pre-Existing Immuno-Reactivity Directed to a Motif in the Fc Region of an IgG4 Monoclonal Antibody TherapeuticChing-Ha (Vicky) Lai, PhD, Senior Staff Scientist, Bioanalytical Sciences, Regeneron Pharmaceuticals, Inc.Development of an Anion Exchange Chromatography Assay for Determining Empty and Full AAV Capsid Content in AAV6.2Thomas Linke, Senior Scientist, Process Development, AstraZenecaA Novel Hydrogen Peroxide Evolved CHO Host Can Improve the Expression of Difficult-to-Express Bispecific AntibodiesRajesh Mistry, Senior Scientist, BioPharmaceuticals Development R&D, AstraZenecaTo Sub 10 pM Affinity and Beyond! Discovery of a Next-Generation Highly Potent Long-Acting Anti IL-5 AntibodyMartin A. Orecchia, PhD, Team Leader, Antibody Discovery, GlaxoSmithKlinePreclinical Pharmacokinetics, Pharmacodynamics and Safety of RO7297089, a Novel Anti-BCMA/CD16a Bispecific Antibody for the Treatment of Multiple MyelomaAyse Meric Ovacik, PhD, Scientist, Developmental Sciences, Genentech, Inc.Analytical Ultracentrifugation: An Auxiliary Tool for Vector CharacterizationRobert Pletzenauer, Head of Process Analytics, Gene Therapy, Process Development, TakedaCharacterization of Adeno-Associated Virus-Based Gene Therapy Products by Mass SpectrometryYi Pu, PhD, Scientist II, Analytical Development, BiogenHCP Analysis by LCMS for BiosimilarsVeronika Reisinger, PhD, Lab Head, Physico Chemical Characterization, Novartis AGAdvancing Mass Spectrometry Technology in cGMP EnvironmentsDa Ren, PhD, Scientific Director, Process Development, Amgen Inc.Enhancing the Prefusion Conformational Stability of SARS-CoV-2 Spike Protein through Structure-Guided DesignTimothy Riley, PhD, Scientist, Amgen Inc.Characterization and Monitoring of Cell Therapy Attributes Using Mass SpectrometryRichard Rogers, PhD, Principal Scientist, Juno Therapeutics, a Bristol-Myers Squibb Co.How Target Biology Drives Bispecific Antibody Product DiscoveryJanine Schuurman, PhD, Senior Vice President, Antibody Research & Technology, Research & Innovation, Genmab BVIs There Safe Storage Temperature for Frozen and Freeze-Dried Biologicals?Evgenyi Y. Shalaev, PhD, Research Investigator, Pharmaceutical Development, AbbVie, Inc.A Novel Next-Generation T Cell Bispecific Antibody PlatformFeng Shu, PhD, Senior Researcher, Chugai Pharmabody Research Pte Ltd.Ultra-Dilute Solution Measurements of Antibody Self-AssociationCharles G. Starr, PhD, Scientist, Developability & Preformulation Sciences, Sanofi GroupStrategies for Greater Expression and ProductionMichaela Strotbek, PhD, Bio Process and Analytical Development, Boehringer Ingelheim Pharma GmbH & Co. KGNMR Tools for the Assessment of Antibody-Drug Candidates Aggregation StatePablo Trigo Mourino, PhD, Senior Scientist, Analytical Research & Development, MSDFAP-CD40, a Novel Tumor-Stroma Targeted CD40 Agonist, Abrogates Systemic Toxicity and Enables Administration of High Doses to Induce Effective Anti-Tumor ImmunityChristine Trumpfheller, PhD, Senior Scientist, Roche Innovation Center ZurichValidation of huFcRn Transgenic Mouse Model to Screen Novel Fc-Engineered Monoclonal and Multi-Specific AntibodiesDelphine Valente, PhD, Head, Pharmacokinetics, Modeling and Simulations, SanofiUsing Neural Networks to Identify ParticlesBernhard Valldorf, PhD, Principal Scientist & Lab Head, Formulation Development, EMD SeronoScreening for Protein-Protein Interactions with Asymmetrical Flow Field-Flow FractionationPer-Olof Wahlund, PhD, Specialist, Biophysics & Injectable Formulation 2, Novo Nordisk ASStructures of Mouse and Human GITR-GITRL Complexes Reveal Unique TNFSF InteractionsFeng Wang, PhD, Associate Director, Recombinant Proteins, Bristol-Myers SquibbThe Role of Monoclonal Antibody Therapeutics in Tackling Global Health ChallengesPauline Williams, CBE, MBBCh, FFPM, FMedSci, Senior Vice President and Head of Global Health R&D, GlaxoSmithKlineNative SEC-MS for Characterizing Therapeutic Monoclonal Antibodies: A Glimpse in the Formation Mechanism of Antibody AggregatesJing Xu, PhD, Scientist I, Analytical Chemistry, BiogenBioanalytical Strategies and Methodologies for Assessing PK and Immunogenicity of Cell/Gene Therapy ProductsTong-Yuan Yang, PhD, Senior Director & Head, PK and Immunogenicity Assay Development, Biologics Development Sciences, Janssen R&D, LLCEfficient NK Cell Redirection by Targeting NKp30Stefan Zielonka, PhD, Associate Director, Protein Engineering & Antibody Technologies, Merck KGaA